HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Codanin-1, the protein encoded by the gene mutated in congenital dyserythropoietic anemia type I (CDAN1), is cell cycle-regulated.

AbstractBACKGROUND:
Congenital dyserythropoietic anemia type I is an inherited autosomal recessive macrocytic anemia associated with ineffective erythropoiesis and the development of secondary hemochromatosis. Distinct erythroid precursors with internuclear chromatin bridges and spongy heterochromatin are pathognomonic for the disease. The mutated gene (CDAN1) encodes a ubiquitously expressed protein of unknown function, codanin-1. Based on the morphological features of congenital dyserythropoietic anemia type I erythroblasts and data on a role in cell cycle progression of codanin-1 homolog in Drosophila we investigated the cellular localization and possible involvement of codanin-1 during the cell cycle.
DESIGN AND METHODS:
Codanin-1 localization was studied by immunofluorescence and immune electron microscopy. Cell cycle expression of codanin-1 was evaluated using synchronized HeLa cells. E2F proteins are the main regulator of G(1)/S transition. An E2F1-inducible cell line (U20S-ER-E2F1) enabled us to study codanin-1 expression following ectopic E2F1 induction. Direct binding of E2F1 to codanin-1 promoter was assessed by chromatin immunoprecipitation. We used a luciferase-reporter plasmid to study activation of CDAN1 transcription by E2F1.
RESULTS:
We localized codanin-1 to heterochromatin in interphase cells. During the cell cycle, high levels of codanin-1 were observed in the S phase. At mitosis, codanin-1 underwent phosphorylation, which coincided with its exclusion from condensed chromosomes. The proximal CDAN1 gene promoter region, containing five putative E2F binding sites, was found to be a direct target of E2F1.
CONCLUSIONS:
Taken together, these data suggest that codanin-1 is a cell cycle-regulated protein active in the S phase. The exact role of codanin-1 during the S phase remains to be determined. Nevertheless this represents the first step towards understanding the function of the proteins involved in congenital dyserythropoietic anemia.
AuthorsSharon Noy-Lotan, Orly Dgany, Roxane Lahmi, Nathaly Marcoux, Tanya Krasnov, Nissan Yissachar, Doron Ginsberg, Benny Motro, Peretz Resnitzky, Isaac Yaniv, Gary M Kupfer, Hannah Tamary
JournalHaematologica (Haematologica) Vol. 94 Issue 5 Pg. 629-37 (May 2009) ISSN: 1592-8721 [Electronic] Italy
PMID19336738 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • CDAN1 protein, human
  • E2F1 Transcription Factor
  • E2F1 protein, human
  • Glycoproteins
  • Heterochromatin
  • Leupeptins
  • Nuclear Proteins
  • Tamoxifen
  • afimoxifene
  • Luciferases
  • benzyloxycarbonylleucyl-leucyl-leucine aldehyde
Topics
  • Amino Acid Sequence
  • Anemia, Dyserythropoietic, Congenital (classification, genetics, pathology)
  • Base Sequence
  • Binding Sites (genetics)
  • Blotting, Western
  • Cell Cycle (physiology)
  • Cell Division (physiology)
  • Cell Line, Tumor
  • Chromatin Immunoprecipitation
  • E2F1 Transcription Factor (genetics, metabolism)
  • G2 Phase (physiology)
  • Gene Expression (drug effects)
  • Glycoproteins (genetics, metabolism)
  • HeLa Cells
  • Heterochromatin (metabolism, ultrastructure)
  • Humans
  • Leupeptins (pharmacology)
  • Luciferases (genetics, metabolism)
  • Microscopy, Confocal
  • Microscopy, Immunoelectron
  • Molecular Sequence Data
  • Mutation
  • Nuclear Proteins
  • Phosphorylation
  • Protein Binding
  • Tamoxifen (analogs & derivatives, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: